Literature DB >> 23713585

The flavoenzyme azobenzene reductase AzoR from Escherichia coli binds roseoflavin mononucleotide (RoFMN) with high affinity and is less active in its RoFMN form.

Simone Langer1, Shinobu Nakanishi, Tilo Mathes, Tanja Knaus, Alexandra Binter, Peter Macheroux, Tomoko Mase, Takuya Miyakawa, Masaru Tanokura, Matthias Mack.   

Abstract

The Gram-positive bacterium Streptomyces davawensis is the only organism known to produce the antibiotic roseoflavin. Roseoflavin is a structural riboflavin analogue and is converted to the flavin mononucleotide (FMN) analogue roseoflavin mononucleotide (RoFMN) by flavokinase. FMN-dependent homodimeric azobenzene reductase (AzoR) (EC 1.7.1.6) from Escherichia coli was analyzed as a model enzyme. In vivo and in vitro experiments revealed that RoFMN binds to the AzoR apoenzyme with an even higher affinity compared to that of the "natural" cofactor FMN. Structural analysis (at a resolution of 1.07 Å) revealed that RoFMN binding did not affect the overall topology of the enzyme and also did not interfere with dimerization of AzoR. The AzoR-RoFMN holoenzyme complex was found to be less active (30% of AzoR-FMN activity) in a standard assay. We provide evidence that the different physicochemical properties of RoFMN are responsible for its reduced cofactor activity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23713585     DOI: 10.1021/bi400348d

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Selective small-molecule inhibition of an RNA structural element.

Authors:  John A Howe; Hao Wang; Thierry O Fischmann; Carl J Balibar; Li Xiao; Andrew M Galgoci; Juliana C Malinverni; Todd Mayhood; Artjohn Villafania; Ali Nahvi; Nicholas Murgolo; Christopher M Barbieri; Paul A Mann; Donna Carr; Ellen Xia; Paul Zuck; Dan Riley; Ronald E Painter; Scott S Walker; Brad Sherborne; Reynalda de Jesus; Weidong Pan; Michael A Plotkin; Jin Wu; Diane Rindgen; John Cummings; Charles G Garlisi; Rumin Zhang; Payal R Sheth; Charles J Gill; Haifeng Tang; Terry Roemer
Journal:  Nature       Date:  2015-09-30       Impact factor: 49.962

2.  Flavoproteins are potential targets for the antibiotic roseoflavin in Escherichia coli.

Authors:  Simone Langer; Masayuki Hashimoto; Birgit Hobl; Tilo Mathes; Matthias Mack
Journal:  J Bacteriol       Date:  2013-07-08       Impact factor: 3.490

3.  Novel riboswitch-binding flavin analog that protects mice against Clostridium difficile infection without inhibiting cecal flora.

Authors:  Kenneth F Blount; Cynthia Megyola; Mark Plummer; David Osterman; Tim O'Connell; Paul Aristoff; Cheryl Quinn; R Alan Chrusciel; Toni J Poel; Heinrich J Schostarez; Catherine A Stewart; Daniel P Walker; Peter G M Wuts; Ronald R Breaker
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

4.  Roseoflavin, a Natural Riboflavin Analogue, Possesses In Vitro and In Vivo Antiplasmodial Activity.

Authors:  Ayman L Hemasa; Matthias Mack; Kevin J Saliba
Journal:  Antimicrob Agents Chemother       Date:  2022-09-12       Impact factor: 5.938

5.  Uptake and Metabolism of Antibiotics Roseoflavin and 8-Demethyl-8-Aminoriboflavin in Riboflavin-Auxotrophic Listeria monocytogenes.

Authors:  Andreas Matern; Danielle Pedrolli; Stephanie Großhennig; Jörgen Johansson; Matthias Mack
Journal:  J Bacteriol       Date:  2016-11-04       Impact factor: 3.490

6.  Structural and kinetic studies on RosA, the enzyme catalysing the methylation of 8-demethyl-8-amino-d-riboflavin to the antibiotic roseoflavin.

Authors:  Chanakan Tongsook; Michael K Uhl; Frank Jankowitsch; Matthias Mack; Karl Gruber; Peter Macheroux
Journal:  FEBS J       Date:  2016-03-17       Impact factor: 5.542

7.  An rfuABCD-Like Operon and Its Relationship to Riboflavin Utilization and Mammalian Infectivity by Borrelia burgdorferi.

Authors:  Matthew K Muramatsu; Jianli Zhou; Bryna L Fitzgerald; Ranjit K Deka; John T Belisle; Michael V Norgard
Journal:  Infect Immun       Date:  2021-07-12       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.